Retracted: Knockdown of lncRNA MNX1‐AS1 suppresses cell proliferation, migration, and invasion in prostate cancer

Abstract

Altered expression of long non‐coding RNA s (lnc RNA s) has been reported in many malignancies, including prostate cancer. However, the role of lnc RNA MNX 1‐ AS 1 in prostate cancer has not been reported. Here, we report that MNX 1‐ AS 1 is expressed in prostate cancer tissues and cells and that si RNA ‐mediated knockdown of MNX 1‐ AS 1 inhibits proliferation, migration, and invasion of prostate cancer DU 145 and PC 3 cells. In addition, down‐regulation of MNX 1‐ AS 1 decreased expression of proliferating cell nuclear antigen, PH ‐3, N‐cadherin, and vimentin, but enhanced expression of E‐cadherin. In conclusion, this is the first report that knockdown of MNX 1‐ AS 1 suppresses prostate cancer cell proliferation, migration, and invasion. We believe that MNX 1‐ AS 1 may be a potential new therapeutic target for prostate cancer patients.

LncRNA MNX1-AS1 drives aggressive laryngeal squamous cell carcinoma progression and serves as a ceRNA to target FoxM1 by sponging microRNA-370

“…LncRNA MNX1-AS1 was first implicated in the progression of ovarian cancer [ 12 ]. Accumulating evidence demonstrated that MNX1-AS1 played an oncogenic role in multiple malignancies including gastric cancer [ 13 ], esophageal squamous cell carcinoma [ 14 ], osteosarcoma [ 15 ], non-small cell lung cancer [ 16 ], hepatocellular carcinoma [ 17 ], prostate cancer [ 18 ], breast cancer [ 19 ] and cervical cancer [ 20 ] and so on. Although one study reported increased MNX1-AS1 expression in LSCC tissues based on the Cancer Genome Atlas Database (TCGA) analysis [ 21 ], little is known about its role and regulation in the pathogenesis of LSCC.…”